Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziftomenib + Venetoclax + Gemtuzumab in Pediatric AML
NCT06448013Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ziftomenib in acute myeloid leukemia (AML) and mixed phenotype acute leukemia (MPAL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events. Started Mar 2025; status: recruiting.
02
Drugs
ziftomenib
03
Conditions
acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT06448013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448013.